diminazene aceturate has been researched along with Alzheimer Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Evans, CE; Good, MA; Heard, DM; Kehoe, PG; Kidd, EJ; Miners, JS; Piva, G; Willis, CL | 1 |
| Duan, R; E, Y; Gong, PY; Jiang, T; Wang, SY; Xue, X; Zhang, QQ; Zhang, YD | 1 |
2 other study(ies) available for diminazene aceturate and Alzheimer Disease
| Article | Year |
|---|---|
ACE2 activation protects against cognitive decline and reduces amyloid pathology in the Tg2576 mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloidogenic Proteins; Angiotensin-Converting Enzyme 2; Animals; Cognitive Dysfunction; Diminazene; Disease Models, Animal; Mice; Mice, Transgenic; Proto-Oncogene Mas | 2020 |
ACE2 activator diminazene aceturate ameliorates Alzheimer's disease-like neuropathology and rescues cognitive impairment in SAMP8 mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Angiotensin I; Angiotensin-Converting Enzyme 2; Animals; Brain Chemistry; Cognitive Dysfunction; Cytokines; Diminazene; Infusions, Parenteral; Male; Maze Learning; Mice; Mice, Neurologic Mutants; Peptide Fragments; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptors, G-Protein-Coupled; tau Proteins | 2020 |